Business Wire

Bayer Innovation Procurement Expands Use of Scientist.com’s AI-Powered Platform for Global R&D Procurement Orchestration

16.6.2025 13:55:00 CEST | Business Wire | Press Release

Share

Bayer AG Innovation Procurement and Scientist.com have signed a multi-year extension that elevates Scientist.com to Bayer’s preferred global channel for sourcing external R&D services.

A Journey from Tactical to Strategic Partnership

The alliance began in 2015, when Bayer adopted Scientist.com’s digital marketplace to streamline and control long-tail spend in preclinical research. Over the years, this relationship has deepened and expanded, reflecting Bayer’s broader shift toward externalizing more of its R&D activities as part of its innovation strategies. What started as a tactical procurement tool has now become Bayer’s preferred global channel for sourcing a wide spectrum of external R&D services.

Comprehensive R&D Outsourcing Capabilities

With the expansion, Scientist.com’s platform will support Bayer across the entire R&D value chain, including:

  • Strategic preclinical supplier management, with guided buying, rate-card compliance, and performance tracking.
  • Clinical development services, offering unified workflows for study execution, biomarker analysis, and central laboratory capabilities.
  • Real-world evidence, data analytics, health economics, and market access solutions, providing rapid access to top-tier data partners.
  • Crop science research, including specialized agriscience testing and regulatory studies.

Driving Digital Transformation and Innovation

By designating Scientist.com as its preferred sourcing channel, Bayer Innovation Procurement has created a single digital entry point for its scientists – enabling access to both strategic and niche providers, automating governance, supporting sustainability goals, and generating actionable insights from aggregated procurement data. This transformation is part of Bayer Innovation Procurement’s strategy to empower Bayer researchers and increase the flexibility and productivity of R&D activities in line with the company wide operating model Dynamic Shared Ownership. The full expansion of Crop Science Research and Clinical Development Services are expected to steadily roll out over the next 6-12 months to enable for the onboarding of Bayer’s full provider list.

Leadership Perspectives

“Scientist.com has proven its value right from the beginning, and this extension makes it the one place our scientists go for most of their external work,” said Dr. Kirstin Meyer, SVP and Head of Pre-clinical Development Research, Bayer AG. “With a single entry point we can reach strategic and niche providers alike, ensure governance, drive our sustainability goals and – critically – generate insights from the aggregated data to guide future decisions.”

“Bayer is showing how a digital procurement orchestration platform can serve as an enterprise solution that streamlines an entire research organization's sourcing processes," said Dr. Dan Kagan, President & COO, Scientist.com. “Together we’re adding new AI tools, deeper data integrations and end-to-end compliance so Bayer teams across Pharma and Crop Science can innovate faster and smarter.”

Scientist.com’s AI-enabled platform combines supplier discovery, competitive bidding, contracting, compliance checks and spend analytics in one secure environment, giving Bayer researchers a seamless path to the expertise they need while unlocking portfolio-level insights from the underlying data.

A Model for the Future of R&D

The evolution of Bayer’s partnership with Scientist.com exemplifies how leading life science organizations are moving beyond tactical procurement toward strategic, digitally enabled R&D outsourcing. This approach not only enhances operational efficiency but also positions Bayer to better leverage global expertise, accelerate innovation, and respond to changing scientific and market demands.

About Scientist.com

Scientist.com is the life-science industry’s premier AI-powered marketplace and procurement-orchestration platform. Founded in 2007 and headquartered in Solana Beach, California, the company simplifies every stage of drug discovery and development by unifying supplier search, competitive bidding, contracting, compliance and analytics in a single, secure workspace. More than 20 of the world’s top 30 pharma companies, 100+ biotech organizations and the US National Institutes of Health rely on Scientist.com to access a vetted network of 6,000+ specialized providers, shorten cycle times and reduce costs while meeting the highest ethical and regulatory standards. Discover how Scientist.com accelerates science at Scientist.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250616174530/en/

Contacts

Scientist.com
Sean Preci
+1 877-644-3044
marketing@scientist.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye